Jane Street
ELVN icon

Jane Street’s Enliven Therapeutics ELVN Stock Holding History

Jane Street’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Buy
40,100
+26,000
+184% +$720K ﹤0.01% 5543
2025
Q4 		$217K Buy
+14,100
New +$281K ﹤0.01% 9551

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's ELVN Position: Q1 2026 in Review

Jane Street increased its Enliven Therapeutics (ELVN) stake by 60% in Q1 2026, buying an estimated $1.71M and bringing the position to 163,519 shares worth $6.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

Jane Street first reported a position in ELVN in Q2 2020 and has held it in 11 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Jane Street held 163,519 shares of Enliven Therapeutics worth $6.41M as of Q1 2026.
  • Jane Street bought 61,548 Enliven Therapeutics shares in Q1 2026, an estimated $1.71M.
  • Enliven Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3137 holding.
  • Jane Street first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 11 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.